Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report

2009 ◽  
Vol 40 (11) ◽  
pp. 1655-1660 ◽  
Author(s):  
Saniye Yumlu ◽  
Robert Barany ◽  
Magdalena Eriksson ◽  
Christoph Röcken
Keyword(s):  
Diabetes Mellitus ◽  
Case Report ◽  
Patients With Diabetes

scholarly journals The treatments of COVID-19 patient with diabetes mellitus: a case report

2021 ◽  
Vol 8 (3) ◽  
pp. 450
Author(s):  
I. Gede Sadu Pratamawerdi ◽  
Jason Raymond Hotama ◽  
I. Made Suma Wirawan
Keyword(s):  
Diabetes Mellitus ◽  
Case Report ◽  
Chronic Illness ◽  
Blood Sugar ◽  
Death Rate ◽  
Glucose Monitoring ◽  
Blood Glucose Monitoring ◽  
Loss Of Consciousness ◽  
Patients With Diabetes ◽  
Strongly Connected

Diabetes mellitus or uncontrolled blood sugar is one of the factors causing the severity risk of COVID-19 infection. The researchers from China and Italy also find a profound connection of the old age patients who have chronic illness comorbid are tend to have a higher risk of enduring serve COVID-19, and have a higher number of deaths. Until this report is written, there are no medicines nor vaccines to treat COVID-19 completely. This article reports KTK, a 57 years old woman, Balinese, was diagnosed with COVID-19 and was treated because of the loss of consciousness. Patient had already done the op debridement amputation for left foot digit II-V and the wound of the patient got worsen. Patient also had blood sugar variability which complicated the insulin therapy and inhibits the patient’s recovery. On her way, the patient’s respiratory system got worsen. Diabetes is strongly connected with a higher risk of severe COVID-19 and has a higher death rate compared to controlled blood sugar. The purpose of the guidance for COVID-19 patients with Diabetes is to prove that comprehensive glycemic control and blood glucose monitoring have a good result of the treatments for COVID-19 patients with Diabetes, also reduce the complication from the comorbid of chronic illness (diabetes), and avoiding the undesirable possibilities about the treatments.

Intramuscular Nerve and Neuromuscular Junction Alteration In Extraocular Muscles of Diabetic Mice

1985 ◽  
Vol 43 ◽  
pp. 682-683
Author(s):  
Bruce R. Pachter
Keyword(s):  
Diabetes Mellitus ◽  
Peripheral Nerves ◽  
Sudden Onset ◽  
Extraocular Muscles ◽  
Diabetic Patients ◽  
Oculomotor Palsy ◽  
Third Nerve Palsy ◽  
Patients With Diabetes ◽  
Intramuscular Nerve ◽  
Oculomotor Nerves

Diabetes mellitus is one of the commonest causes of neuropathy. Diabetic neuropathy is a heterogeneous group of neuropathic disorders to which patients with diabetes mellitus are susceptible; more than one kind of neuropathy can frequently occur in the same individual. Abnormalities are also known to occur in nearly every anatomic subdivision of the eye in diabetic patients. Oculomotor palsy appears to be common in diabetes mellitus for their occurrence in isolation to suggest diabetes. Nerves to the external ocular muscles are most commonly affected, particularly the oculomotor or third cranial nerve. The third nerve palsy of diabetes is characteristic, being of sudden onset, accompanied by orbital and retro-orbital pain, often associated with complete involvement of the external ocular muscles innervated by the nerve. While the human and experimental animal literature is replete with studies on the peripheral nerves in diabetes mellitus, there is but a paucity of reported studies dealing with the oculomotor nerves and their associated extraocular muscles (EOMs).

Desmopressin Stimulates Parallel Norepinephrine and Tissue Plasminogen Activator Release in Normal Subjects and Patients with Diabetes Mellitus

1988 ◽  
Vol 59 (02) ◽  
pp. 269-272 ◽  
Author(s):  
M B Grant ◽  
C Guay ◽  
R Lottenberg
Keyword(s):  
Diabetes Mellitus ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Time Course ◽  
Vascular Endothelial Cells ◽  
Normal Subjects ◽  
Plasma Norepinephrine ◽  
Endogenous Catecholamine ◽  
Tissue Plasminogen ◽  
Patients With Diabetes

SummaryDesmopressin acetate administration markedly stimulates release of tissue plasminogen activator (t-PA) from vascular endothelial cells. The mechanism for this effect is unknown. Because infusion of epinephrine has been shown to increase t-PA levels, we examined the role of endogenous catecholamine mediation of t-PA release by desmopressin. Intravenous desmopressin acetate (0.3 μg/kg) was infused over 30 min in 9 controls and 11 subjects with diabetes mellitus, a condition associated with abnormalities of the fibrinolytic system. Plasma was collected in the supine, overnight fasted state at 15 min intervals (0-60 min) for measurement of t-PA activity, t-PA antigen and fractionated catecholamines. t-PA activity peaked at 30-45 min and subsequently decreased. The norepinephrine levels paralleled the t-PA activity. t-PA activity increased 10-fold from 0.14 ± .12 to 1.49 ± 0.79 IU/ml (Mean ± SD) and plasma norepinephrine increased 2- fold from 426 ± 90 to 780 ± 292 pg/ml. However, epinephrine and dopamine levels did not change significantly. The response to desmopressin of control and diabetic subjects was not shown to differ and their data were combined. We conclude that desmopressin increases plasma norepinephrine in addition to t-PA and that the parallel time course of change suggests a possible role for norepinephrine in mediating endothelial cell t-PA release.

Sign in / Sign up

Export Citation Format

Share Document